Company Filing History:
1 out of 34 
1 out of 43 Years Active: 2021
Title: Ryota Horibe: Innovator in Cancer Treatment
Introduction
Ryota Horibe is a notable inventor based in Sapporo, Japan. He has made significant contributions to the field of cancer research, particularly in the development of tumor antigen peptides. His work aims to enhance the prevention and treatment of cancer, showcasing his dedication to medical innovation.
Latest Patents
Horibe holds a patent for a tumor antigen peptide. The objective of this patent is to provide a peptide that is specifically presented on cancer cells and cancer stem cells. This invention includes a pharmaceutical composition that is useful for the prevention and/or treatment of cancer, containing the peptide as an active ingredient. The patent describes a BORIS-derived partial peptide belonging to isoform A or C or subfamily 5 or 6, along with a polynucleotide encoding the peptide. This composition is designed to induce cytotoxic T lymphocytes (CTLs) for effective cancer treatment.
Career Highlights
Throughout his career, Ryota Horibe has worked with esteemed institutions such as Sapporo Medical University and Medical & Biological Laboratories Co., Ltd. His experience in these organizations has contributed to his expertise in medical research and innovation.
Collaborations
Horibe has collaborated with notable colleagues, including Toshihiko Torigoe and Eri Atsuyama. These partnerships have likely enriched his research and development efforts in the field of cancer treatment.
Conclusion
Ryota Horibe's contributions to cancer research through his innovative patent demonstrate his commitment to improving medical treatments. His work continues to inspire advancements in the fight against cancer.